Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications
Authors
Keywords
-
Journal
ACTA PHARMACOLOGICA SINICA
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-02-12
DOI
10.1038/s41401-020-00584-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Repeated EUS-FNA of pancreatic masses after nondiagnostic or inconclusive results: systematic review and meta-analysis
- (2020) Andrea Lisotti et al. GASTROINTESTINAL ENDOSCOPY
- Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
- (2020) Louis Buscail et al. Nature Reviews Gastroenterology & Hepatology
- Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer
- (2020) Fumiaki Watanabe et al. PLoS One
- Inhibition of TGF-β signalling in combination with nal-IRI plus 5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models
- (2020) Eunji Hong et al. Scientific Reports
- ATM Serine/Threonine Kinase and its Role in Pancreatic Risk
- (2020) Neha Nanda et al. Genes
- Human organoids: model systems for human biology and medicine
- (2020) Jihoon Kim et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Epidemiology and burden of pancreatic cancer
- (2019) Patrick Maisonneuve PRESSE MEDICALE
- TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status
- (2019) Chen Liang et al. Autophagy
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion
- (2019) E M O’Reilly et al. ANNALS OF ONCOLOGY
- Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer
- (2019) Chen Liang et al. GUT
- Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer
- (2019) Kyle C. Cuneo et al. JOURNAL OF CLINICAL ONCOLOGY
- ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications
- (2019) Samantha A. Armstrong et al. MOLECULAR CANCER THERAPEUTICS
- Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
- (2019) Joaquin Mateo et al. LANCET ONCOLOGY
- Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains
- (2019) Dongju Park et al. PLoS One
- KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study
- (2018) Yutaka Nakano et al. BRITISH JOURNAL OF CANCER
- SMAD4Gene Mutation Renders Pancreatic Cancer Resistance to Radiotherapy through Promotion of Autophagy
- (2018) Feng Wang et al. CLINICAL CANCER RESEARCH
- The role of TGF-β/SMAD4 signaling in cancer
- (2018) Ming Zhao et al. International Journal of Biological Sciences
- Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer
- (2018) Eric Van Cutsem et al. INTERNATIONAL JOURNAL OF CANCER
- Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer
- (2018) Chunling Hu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Emerging strategies in BRCA-positive pancreatic cancer
- (2018) Adam Kowalewski et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Smad4/DPC4
- (2018) Aoife J McCarthy et al. JOURNAL OF CLINICAL PATHOLOGY
- Therapeutic developments in pancreatic cancer: current and future perspectives
- (2018) John P. Neoptolemos et al. Nature Reviews Gastroenterology & Hepatology
- MutantKRASCirculating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring
- (2018) Ruth Perets et al. ONCOLOGIST
- Challenges in diagnosis of pancreatic cancer
- (2018) Lulu Zhang et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Organoid profiling identifies common responders to chemotherapy in pancreatic cancer
- (2018) Hervé Tiriac et al. Cancer Discovery
- Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection
- (2018) Clare Fiala et al. BMC Medicine
- Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers
- (2018) V. Chung et al. Clinical & Translational Oncology
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic testing for pancreatic cancer in clinical practice as real-world evidence
- (2018) Hideyuki Hayashi et al. PANCREATOLOGY
- Ki67 and P53 in Relation to Disease Progression in Metastatic Pancreatic Cancer: a Single Institution Analysis
- (2018) Sally Temraz et al. PATHOLOGY & ONCOLOGY RESEARCH
- Mutant p53 as a guardian of the cancer cell
- (2018) Fiamma Mantovani et al. CELL DEATH AND DIFFERENTIATION
- Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer
- (2018) Vincent Bernard et al. GASTROENTEROLOGY
- Pathways of Progression From Intraductal Papillary Mucinous Neoplasm to Pancreatic Ductal Adenocarcinoma Based on Molecular Features
- (2018) Yuko Omori et al. GASTROENTEROLOGY
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
- (2018) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study
- (2018) Vasilios Karavasilis et al. Targeted Oncology
- The Strain Ratio as Obtained by Endoscopic Ultrasonography Elastography Correlates With the Stroma Proportion and the Prognosis of Local Pancreatic Cancer
- (2018) Si Shi et al. ANNALS OF SURGERY
- Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer
- (2017) Angela Chou et al. GUT
- The Role of PALB2 in the DNA Damage Response and Cancer Predisposition
- (2017) Thales Nepomuceno et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma
- (2017) Chen Liang et al. MOLECULAR CANCER RESEARCH
- Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer
- (2017) Prasenjit Dey et al. NATURE
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
- (2017) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enhancement of cytotoxic effects of gemcitabine by Dclk1 inhibition through suppression of Chk1 phosphorylation in human pancreatic cancer cells
- (2017) Daichi Kawamura et al. ONCOLOGY REPORTS
- Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers
- (2017) Joshua D. Cohen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
- (2017) Johann de Bono et al. Cancer Discovery
- Efforts to Develop KRAS Inhibitors
- (2017) Matthew Holderfield Cold Spring Harbor Perspectives in Medicine
- Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy
- (2017) Vincent Chung et al. JAMA Oncology
- A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer
- (2016) B. H. O'Neil et al. ANNALS OF ONCOLOGY
- Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2
- (2016) Scott A. Foster et al. CANCER CELL
- A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer
- (2016) D. J. Renouf et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation
- (2016) Christopher J. Tape et al. CELL
- TGF-β Tumor Suppression through a Lethal EMT
- (2016) Charles J. David et al. CELL
- FBW7 (F-box and WD Repeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancreatic Cancer
- (2016) S. Ji et al. CLINICAL CANCER RESEARCH
- Islet biology, the CDKN2A/B locus and type 2 diabetes risk
- (2016) Yahui Kong et al. DIABETOLOGIA
- Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities
- (2016) Barbara Bournet et al. EUROPEAN JOURNAL OF CANCER
- Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib
- (2016) Ganji Purnachandra Nagaraju et al. EUROPEAN JOURNAL OF CANCER
- Targeting mutant p53 in cancer: a long road to precision therapy
- (2016) Fiamma Mantovani et al. FEBS Journal
- Mounting Pressure in the Microenvironment: Fluids, Solids, and Cells in Pancreatic Ductal Adenocarcinoma
- (2016) Christopher C. DuFort et al. GASTROENTEROLOGY
- Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib
- (2016) Pascal Hammel et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)
- (2016) Katsuhiko Uesaka et al. LANCET
- ATM Mutations in Cancer: Therapeutic Implications
- (2016) M. Choi et al. MOLECULAR CANCER THERAPEUTICS
- Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma
- (2016) Anne M Noonan et al. MOLECULAR THERAPY
- Genomic analyses identify molecular subtypes of pancreatic cancer
- (2016) Peter Bailey et al. NATURE
- P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment
- (2016) Jana K. Striefler et al. PATHOLOGY RESEARCH AND PRACTICE
- KRAS-related proteins in pancreatic cancer
- (2016) Karen M. Mann et al. PHARMACOLOGY & THERAPEUTICS
- Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer
- (2016) Jean-Luc Van Laethem et al. Targeted Oncology
- p53 and p16Ink4a/p19Arf Loss Promotes Different Pancreatic Tumor Types from PyMT-Expressing Progenitor Cells
- (2016) Stephanie Azzopardi et al. NEOPLASIA
- KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
- (2016) Daniel Zeitouni et al. Cancers
- A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer
- (2015) Rory J. Makielski et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer
- (2015) S. Kordes et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma
- (2015) Martin C. Whittle et al. CELL
- Organoid Models of Human and Mouse Ductal Pancreatic Cancer
- (2015) Sylvia F. Boj et al. CELL
- ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer
- (2015) Shunrong Ji et al. CELL RESEARCH
- Inhibitors of Ras-SOS Interactions
- (2015) Shaoyong Lu et al. ChemMedChem
- A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma
- (2015) A. H. Ko et al. CLINICAL CANCER RESEARCH
- Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
- (2015) A. D. Cox et al. CLINICAL CANCER RESEARCH
- FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
- (2015) J. A. Beaver et al. CLINICAL CANCER RESEARCH
- Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial
- (2015) L. A. Chantrill et al. CLINICAL CANCER RESEARCH
- BRAF inhibitors: the current and the future
- (2015) Weijiang Zhang CURRENT OPINION IN PHARMACOLOGY
- Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma
- (2015) Spring Holter et al. JOURNAL OF CLINICAL ONCOLOGY
- Small Molecule Binding Sites on the Ras:SOS Complex Can Be Exploited for Inhibition of Ras Activation
- (2015) Jon J. G. Winter et al. JOURNAL OF MEDICINAL CHEMISTRY
- KRAS Mutation Status Is Not a Predictor for Tumor Response and Survival in Rectal Cancer Patients Who Received Preoperative Radiotherapy With 5-Fluoropyrimidine Followed by Curative Surgery
- (2015) Jeong Won Lee et al. MEDICINE
- Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer
- (2015) Kjersti Tjensvoll et al. Molecular Oncology
- Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
- (2015) Xiaofeng Zheng et al. NATURE
- Whole genomes redefine the mutational landscape of pancreatic cancer
- (2015) Nicola Waddell et al. NATURE
- Ataxia-telangiectasia–Mutated Protein Kinase Levels Stratify Patients With Pancreatic Adenocarcinoma Into Prognostic Subgroups With Loss Being a Strong Indicator of Poor Survival
- (2015) Carsten Kamphues et al. PANCREAS
- Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
- (2015) Agnieszka K. Witkiewicz et al. Nature Communications
- Targeting Oncogenic Mutant p53 for Cancer Therapy
- (2015) Alejandro Parrales et al. Frontiers in Oncology
- Pancreatic Adenocarcinoma
- (2015) David P. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma
- (2014) D. Propper et al. ANNALS OF ONCOLOGY
- Redox-responsive targeted gelatin nanoparticles for delivery of combination wt-p53 expressing plasmid DNA and gemcitabine in the treatment of pancreatic cancer
- (2014) Jing Xu et al. BMC CANCER
- Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
- (2014) T Golan et al. BRITISH JOURNAL OF CANCER
- Dragging Ras Back in the Ring
- (2014) Andrew G. Stephen et al. CANCER CELL
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- Having Pancreatic Cancer with Tumoral Loss of ATM and Normal TP53 Protein Expression Is Associated with a Poorer Prognosis
- (2014) H. Kim et al. CLINICAL CANCER RESEARCH
- A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
- (2014) Jeffrey R. Infante et al. EUROPEAN JOURNAL OF CANCER
- BRCA1, BRCA2, PALB2 and CDKN2A mutations in familial pancreatic cancer: a PACGENE study
- (2014) David B. Zhen et al. GENETICS IN MEDICINE
- PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines
- (2014) Patricia Izetti et al. INVESTIGATIONAL NEW DRUGS
- Breast-Cancer Risk in Families with Mutations in PALB2
- (2014) Antonis C. Antoniou et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- KRAS Mutations in Codon 12 or 13 Are Associated With Worse Prognosis in Pancreatic Ductal Adenocarcinoma
- (2014) Bruno V. Sinn et al. PANCREAS
- Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activity
- (2014) J Xu et al. Cell Death & Disease
- Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer
- (2014) Dana B. Cardin et al. Cancer Medicine
- Immunohistochemically Detected Expression of 3 Major Genes (CDKN2A/p16, TP53, and SMAD4/DPC4) Strongly Predicts Survival in Patients With Resectable Pancreatic Cancer
- (2013) Minoru Oshima et al. ANNALS OF SURGERY
- Failure Patterns in Resected Pancreas Adenocarcinoma
- (2013) Jordan M. Winter et al. ANNALS OF SURGERY
- Roles for KRAS in Pancreatic Tumor Development and Progression
- (2013) Marina Pasca di Magliano et al. GASTROENTEROLOGY
- Senescence in pancreatic carcinogenesis: from signalling to chromatin remodelling and epigenetics
- (2013) Shiv K Singh et al. GUT
- Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine
- (2013) Hong-Quan Duong et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Expression profiling of cell cycle genes in human pancreatic islets with and without type 2 diabetes
- (2013) Jalal Taneera et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells
- (2013) Cosimo Commisso et al. NATURE
- Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
- (2013) Jaekyoung Son et al. NATURE
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetic Alterations of K-ras, p53, c-erbB-2, and DPC4 in Pancreatic Ductal Adenocarcinoma and Their Correlation With Patient Survival
- (2013) Sang Hyun Shin et al. PANCREAS
- Mutant KRAS is a druggable target for pancreatic cancer
- (2013) E. Zorde Khvalevsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tumour-associated mutant p53 drives the Warburg effect
- (2013) Cen Zhang et al. Nature Communications
- Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma
- (2012) J. B. Bachet et al. ANNALS OF ONCOLOGY
- BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer
- (2012) A. Gonçalves et al. ANNALS OF ONCOLOGY
- Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
- (2012) Paolo P. Provenzano et al. CANCER CELL
- Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
- (2012) Haoqiang Ying et al. CELL
- Regulation of EMT by TGFβ in cancer
- (2012) Carl-Henrik Heldin et al. FEBS LETTERS
- What We Have Learned About Pancreatic Cancer From Mouse Models
- (2012) Pedro A. Pérez–Mancera et al. GASTROENTEROLOGY
- Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104)
- (2012) Volker Heinemann et al. GUT
- A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer
- (2012) Sil Kordes et al. INVESTIGATIONAL NEW DRUGS
- Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
- (2012) Meredith A. Collins et al. JOURNAL OF CLINICAL INVESTIGATION
- Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer
- (2012) Takeshi Ogura et al. JOURNAL OF GASTROENTEROLOGY
- Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
- (2012) Andrew V. Biankin et al. NATURE
- SMAD4 Genetic Alterations Predict a Worse Prognosis in Patients With Pancreatic Ductal Adenocarcinoma
- (2012) Puneet Singh et al. PANCREAS
- The Predictive Role of p16 Deletion, p53 Deletion, and Polysomy 9 and 17 in Pancreatic Ductal Adenocarcinoma
- (2012) Yanli Luo et al. PATHOLOGY & ONCOLOGY RESEARCH
- Metastatic Pancreatic Cancer Is Dependent on Oncogenic Kras in Mice
- (2012) Meredith A. Collins et al. PLoS One
- Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity
- (2012) T. Maurer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
- (2012) Eric A. Collisson et al. Cancer Discovery
- Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer
- (2011) R A Smith et al. BRITISH JOURNAL OF CANCER
- SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis
- (2011) D Li et al. CELL DEATH AND DIFFERENTIATION
- Routine testing for PALB2 mutations in familial pancreatic cancer families and breast cancer families with pancreatic cancer is not indicated
- (2011) Femme Harinck et al. EUROPEAN JOURNAL OF HUMAN GENETICS
- A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy
- (2011) György Bodoky et al. INVESTIGATIONAL NEW DRUGS
- A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer
- (2011) A. B. El-Khoueiry et al. INVESTIGATIONAL NEW DRUGS
- Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation ofSmad4(Dpc4)Immunostaining With Pattern of Disease Progression
- (2011) Christopher H. Crane et al. JOURNAL OF CLINICAL ONCOLOGY
- Pancreatic cancer
- (2011) Audrey Vincent et al. LANCET
- Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy
- (2011) S. T. Kim et al. MOLECULAR CANCER THERAPEUTICS
- Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
- (2011) Eric A Collisson et al. NATURE MEDICINE
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- p16Ink4a overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors
- (2011) C Romagosa et al. ONCOGENE
- EUS-FNA Mutational Analysis in Differentiating Autoimmune Pancreatitis and Pancreatic Cancer
- (2011) Asif Khalid et al. PANCREATOLOGY
- ATM Mutations in Patients with Hereditary Pancreatic Cancer
- (2011) Nicholas J. Roberts et al. Cancer Discovery
- Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
- (2010) Milind M Javle et al. BMC CANCER
- The ARF tumor suppressor: Structure, functions and status in cancer
- (2010) Peggy Ozenne et al. INTERNATIONAL JOURNAL OF CANCER
- Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras
- (2010) Synne Wedén et al. INTERNATIONAL JOURNAL OF CANCER
- Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer
- (2010) M. C. Villarroel et al. MOLECULAR CANCER THERAPEUTICS
- Susceptibility Pathways in Fanconi's Anemia and Breast Cancer
- (2010) Alan D. D'Andrea NEW ENGLAND JOURNAL OF MEDICINE
- Genomic Instability at Both the Base Pair Level and the Chromosomal Level Is Detectable in Earliest PanIN Lesions in Tissues of Chronic Pancreatitis
- (2010) Mario Baumgart et al. PANCREAS
- PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain
- (2009) Jeremy M.R. Lambert et al. CANCER CELL
- FAM/USP9x, a Deubiquitinating Enzyme Essential for TGFβ Signaling, Controls Smad4 Monoubiquitination
- (2009) Sirio Dupont et al. CELL
- The Secret Life of Smad4
- (2009) Jeffrey L. Wrana CELL
- SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer
- (2009) A. Blackford et al. CLINICAL CANCER RESEARCH
- Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
- (2009) David Cunningham et al. JOURNAL OF CLINICAL ONCOLOGY
- DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer
- (2009) Christine A. Iacobuzio-Donahue et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification and Characterization of a Novel Anticancer Agent With Selectivity Against Deleted in Pancreatic Cancer Locus 4 (DPC4)-Deficient Pancreatic and Colon Cancer Cells
- (2009) Hong Wang et al. PANCREAS
- Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer
- (2009) J. P. Morton et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene
- (2009) S. Jones et al. SCIENCE
- TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use
- (2009) M. Olivier et al. Cold Spring Harbor Perspectives in Biology
- Polymorphisms of p16, p27, p73, and MDM2 Modulate Response and Survival of Pancreatic Cancer Patients Treated with Preoperative Chemoradiation
- (2008) Jinyun Chen et al. ANNALS OF SURGICAL ONCOLOGY
- Pancreatic Cancer
- (2008) Anirban Maitra et al. Annual Review of Pathology-Mechanisms of Disease
- Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
- (2008) Volker Heinemann et al. BMC CANCER
- Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
- (2008) Brian M. Wolpin et al. JOURNAL OF CLINICAL ONCOLOGY
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
- (2008) S. Jones et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search